STOCK TITAN

Odyssey Therapeutics (ODTX) 10-Q Filings

ODTX NASDAQ

Here are the 10-Q quarterly reports from Odyssey Therapeutics, Inc. (ODTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-Q covers the quarterly report filed between annual reports, so if you follow ODTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ODTX filings page.

Rhea-AI Summary

Odyssey Therapeutics, Inc. reported a third-quarter 2026 net loss of $53.059 million, compared with $35.462 million in 2025; nine-month net loss was $144.109 million versus $115.132 million. Collaboration revenue was $0 for the nine months, compared with $2.976 million in 2025, and $0 for the quarter versus $99,000.

Research and development expenses were $42.121 million in the quarter versus $26.325 million, while nine-month operating cash use was $117.085 million compared with $104.139 million. Cash, cash equivalents and marketable securities totaled $387.0 million as of September 30, 2026; management believes these resources will fund operations for at least twelve months from issuance of the statements. Common-stock issuance in the May 2026 IPO generated $288.194 million in net financing cash proceeds.

Odyssey is a clinical-stage biopharmaceutical company with no approved products or product-sales revenue. OD-001 has presented efficacy and supporting analyses from the 12-week induction period of its Phase 2a clinical trial; OD-002 has completed IND-enabling studies.

Rhea-AI Summary

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases. Its lead programs are OD-001, an oral RIPK2 inhibitor with phase 2a proof-of-concept in ulcerative colitis, and OD-002, an oral SLC15A4 inhibitor in IND-enabling studies.

For the six months ended June 30, 2026, the company reported no collaboration revenue and a net loss of $91.1 million, compared with a $79.7 million net loss a year earlier, reflecting continued investment in its pipeline and higher non-cash contingent consideration expense.

After a May 2026 IPO and concurrent private placement, Odyssey strengthened its balance sheet, ending June 30, 2026 with $433.1 million in cash, cash equivalents and marketable securities. Management estimates this capital will fund operating expenses and capital expenditures into the second half of 2028, while substantial future losses remain likely.

Rhea-AI Summary

Odyssey Therapeutics reported a net loss of $38.3 million for the quarter ended March 31, 2026, broadly in line with the prior year. Collaboration revenue fell to zero from $1.9 million as prior Pfizer and Johnson & Johnson research agreements were completed.

Research and development expense was $32.3 million and general and administrative expense was $7.4 million, reflecting continued investment in its autoimmune and inflammatory disease pipeline. Cash, cash equivalents and marketable securities totaled $175.7 million at quarter end.

After the quarter, Odyssey completed an IPO and concurrent private placement, raising net proceeds of about $288.7 million. Together with existing cash, management believes this will fund operations for at least twelve months from issuance of these financial statements.